H.R. 9635 aims to amend existing laws related to the Federal Food, Drug, and Cosmetic Act. The bill proposes special rules that would allow the continued review of human drug and device submissions even during periods when the government is not funded, known as a lapse of appropriations. This means that the approval process for new drugs and medical devices would not be halted due to budgetary issues.
Supporters of H.R. 9635 have praised the bill for its potential to ensure that critical medical advancements are not delayed due to funding issues. They argue that maintaining the review process for drugs and devices is essential for public health, especially during emergencies when timely access to new treatments can save lives.
Critics of H.R. 9635 have expressed concerns that allowing reviews to continue during funding lapses could undermine the regulatory process. They argue that it may lead to rushed approvals without adequate oversight, potentially compromising patient safety. Some media outlets have highlighted the risks of prioritizing speed over thorough evaluation in drug and device approval.
All donors are from Applied Materials, Inc., which may have an interest in the continued review of human drug and device submissions. However, the bill primarily addresses procedural issues during a lapse of appropriations, which may not directly benefit the company. The risk score is medium due to the concentration of donations from a single company.
Top industries and organizations funding Kevin Mullin, from FEC data.
Source: FEC campaign finance records
